1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
The tumor suppressor p53 is often referred to as "the guardian of the genome" because of its central role in the cellular response to oncogenic stress and prevention of tumor development. Mutations of p53 in acute myeloid leukemia (AML) are rare but resistance to chemotherapy has been reported because of the deregulation of the p53 signaling and differentiation pathways. It is known that the interaction of the vitamin D metabolite 1,25-dihydroxyvitamin D(3) (1,25D) with its functional vitamin D receptor leads to differentiation, G(1) arrest, and increased cell survival in p53-null AML cells. However, there are no reports on the effect of 1,25D in leukemia cells expressing wild-type p53. Here, we examine vitamin D signaling in AML cells MOLM-13 and OCI-AML3 expressing wild-type p53 in the presence and absence of the MDM2 antagonist nutlin-3. We find that 1,25D alone induces monocytic differentiation in these cell lines similar to that seen in p53-null AML cells, suggesting that the presence of wild-type p53 is compatible with activation of vitamin D signaling. Combination of nutlin-3a with 1,25D accelerated programmed cell death, likely because of enhanced nutlin-induced upregulation of the proapoptotic PIG-6 protein and downregulation of antiapoptotic BCL-2, MDMX, human kinase suppressor of Ras 2, and phosphorylated extracellular signal-regulated kinase 2.
Thompson
Thelma
T
Discovery Oncology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, New Jersey, USA.
Andreeff
Michael
M
Studzinski
George P
GP
Vassilev
Lyubomir T
LT
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002117:Calcitriol / Q000008:administration & dosage / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D016158:Genes, p53; D018922:HL-60 Cells; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000494:pharmacology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009000:Monocytes / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000008:administration & dosage* / Q000494:pharmacology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors*; D015854:Up-Regulation / Q000187:drug effects
D007093:Imidazoles; D010879:Piperazines; C482205:nutlin 3; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D002117:Calcitriol
Cancer Res. 2003 Mar 15;63(6):1325-32
12649194
Proc Soc Exp Biol Med. 1985 Jul;179(3):288-95
3858884
Endocr Rev. 1982 Fall;3(4):331-66
6295752
Blood. 1994 Jul 1;84(1):256-61
8018920
J Exp Med. 2006 Feb 20;203(2):371-81
16446383
J Clin Invest. 2001 Sep;108(6):851-9
11560954
Nature. 1997 Sep 18;389(6648):300-5
9305847
Cancer Res. 2001 Mar 1;61(5):1810-5
11280728
Cancer Res. 2007 Apr 1;67(7):3210-9
17409429
Blood. 1983 Oct;62(4):709-21
6192859
Mol Cancer Ther. 2008 Sep;7(9):3047-55
18790784
N Engl J Med. 1999 Sep 30;341(14):1051-62
10502596
Leukemia. 1997 Sep;11(9):1469-77
9305600
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12792-6
9371754
Blood. 2005 Nov 1;106(9):3150-9
16014563
Clin Cancer Res. 2008 Aug 15;14(16):5000-5
18698017
Cancer Res. 2006 May 1;66(9):4574-83
16651407
J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):47-55
16046262
J Biol Chem. 2004 Dec 17;279(51):53015-22
15471885
Science. 2004 Feb 6;303(5659):844-8
14704432
Oncol Res. 2007;16(11):517-25
18306931
Leukemia. 2003 Jan;17(1):120-4
12529668
Cell Cycle. 2004 Jul;3(7):900-4
15254433
Hematol J. 2004;5(6):489-95
15570290
Trends Mol Med. 2007 Jan;13(1):23-31
17126603
Oncogene. 2006 Sep 14;25(41):5640-7
16619034
Cancer Res. 1985 Aug;45(8):3898-905
3860289
J Cell Physiol. 2006 Nov;209(2):253-60
16883571
Exp Cell Res. 2007 Aug 15;313(14):3034-45
17599832
Curr Top Med Chem. 2006;6(12):1267-71
16848740
Cell Cycle. 2008 Jun 1;7(11):1604-12
18520179
Cell Growth Differ. 2000 Nov;11(11):561-71
11095245
Oncogene. 1995 Mar 16;10(6):1053-9
7700629
Cell Cycle. 2004 Apr;3(4):419-21
15004525
Clin Exp Immunol. 1989 May;76(2):274-7
2758696
Cell. 1993 Aug 27;74(4):609-19
8358790
Int J Cancer. 2006 Jun 15;118(12):3012-21
16395705
Blood. 1994 Oct 15;84(8):2412-21
7919360
Leuk Lymphoma. 2000 Oct;39(3-4):257-70
11342306
Endocr Rev. 1995 Apr;16(2):200-57
7781594
Clin Cancer Res. 2001 Apr;7(4):1043-51
11309356
J Cell Biochem. 2001;80(4):471-82
11169731
Science. 2004 Feb 13;303(5660):1010-4
14963330
Cancer Res. 2004 Aug 1;64(15):5425-33
15289351
Oncogene. 1994 Nov;9(11):3397-406
7936668
J Cell Physiol. 2004 Mar;198(3):333-42
14755538
Nature. 1997 May 15;387(6630):296-9
9153395
Mol Cancer Ther. 2008 Sep;7(9):2798-806
18790760
Cancer Res. 1996 Jan 15;56(2):264-7
8542578
Oncogene. 1994 Jun;9(6):1799-805
8183579